Navigation Links
Pharmaceutical Insiders with Proof of Company’s Improper Relationships: Federal Law Offers Whistleblowers Opportunity for Sizable Financial Compensation, Parker Waichman LLP Says
Date:10/22/2013

New York, New York (PRWEB) October 22, 2013

Parker Waichman LLP, a national law firm that represents whistleblowers in qui tam cases, is looking to inform potential whistleblowers in the pharmaceutical industry that if they have proof of an improper relationship between their firm and a government entity, such as a regulating agency, financial opportunities abound, courtesy of the federal government.

One recent example involving a potential unlawful relationship between a regulator and one or more pharmaceutical companies centers on a scientific panel charged with shaping the federal government’s policy for testing the safety and effectiveness of painkillers. As The Washington Post reported on Oct. 6, 2013, major pharmaceutical companies funded the panel, paying hundreds of thousands of dollars for an opportunity “to affect the thinking” of the U.S. Food and Drug Administration (FDA), according to hundreds of emails that were obtained via a public records request.

The emails show, The Washington Post noted, that the pharmaceutical companies paid as much as $25,000 to attend panel meetings. Two medical professors, Robert Dworkin of the University of Rochester and Dennis Turk of the University of Washington, organized the panel, and as The Washington Post reported, the emails mainly described their efforts at financing and organizing the group and its meetings.

The Post article further noted that the FDA has been disparaged for failing to put in place stricter precautions that might have helped the U.S. to avoid the, “epidemic of addiction to prescription drugs,” such as Oxycontin and other opioids.

Sen. Joe Manchin III has since called for an investigation into “pay to play” allegations regarding the scientific panel, The Washing Post reported on Oct. 9, 2013. In a letter to FDA Commissioner Margaret Hamburg, noted in the Oct. 9 Washington Post report, Manchin requested a list of documents be turned over to his office; the list included the names of all the companies that had paid to attend the panel’s meetings, as well as how much they paid. Also of interest, the Post article added, were any emails between the companies’ event organizers and FDA officials.

The Oct. 9 Washing Post report added that Manchin (D-W. Va.) had been pushing the FDA to place stricter limits on hydrocodone — a key ingredient in the painkillers Vicodin and Lortab — due to its, “addictive power and widespread availability.” Pharmacy companies and others have disagreed with this tact, the Post report noted, claiming that additional restrictions, “could unfairly put the drugs out of reach for patients who need them.”

In recent years many pharmaceutical employees have come forward to report fraudulent billing, illegal marketing techniques and undisclosed drug side effects. These people – known as whistleblowers – have helped the federal government recover billions of dollars obtained illegally by pharmaceutical companies. Whistleblowers have also helped save the lives of countless prescription drug and medical device users who were previously unaware of the side effects of their device or prescription.

Specifically, the Civil War-era False Claims Act provides whistleblowers with protection and the opportunity for compensation. Amendments added to the Act in 1986 helped to incentivize whistleblowers to come forward, primarily by raising the amounts that can be charged for damages and penalties; whistleblowers can be awarded millions of dollars today; between 15% and 30% of the amount recovered by the government.

Anyone who possesses proof that a pharmaceutical company has engaged in an unlawful relationship and is thereby committing fraudulent activity against the federal government is encouraged to contact us. Please view our Qui Tam page or call 1-800-LAW-INFO (1-800-529-4636).

Contact:
Parker Waichman LLP
Gary Falkowitz, Managing Attorney
1+(800) LAW-INFO
1+(800) 529-4636
http://www.yourlawyer.com

Read the full story at http://www.prweb.com/releases/whistleblower_FDA_panel/painkillers/prweb11256696.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
2. MSU invention could help pharmaceutical industry save money
3. Nobel laureate to keynote international pharmaceutical conference at URI
4. 5 more pharmaceutical companies join NIH initiative to speed therapeutic discovery
5. Is it constitutional for states to regulate pharmaceutical gifts and meals to doctors?
6. Pharmica Consulting to Hold HIT Conference for the Pharmaceutical Industry
7. Scientists use sound waves to levitate liquids, improve pharmaceuticals
8. Medical care presents update on pharmaceutical health services research
9. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
10. Environmentally friendly chemistry important for manufacturing pharmaceuticals
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, ... their Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, ... generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ( ... diversifiée innovante, est ravie d,annoncer les excellents résultats semestriels ... période précédente correspondante. Une présentation complète « Résultats et mise ... consultée ici . Faits marquants ... 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
Breaking Medicine Technology: